P3.01-075 Afatinib Dose Adjustment: Effect on Safety, Efficacy and Patient-Reported Outcomes in the LUX-Lung 3/6 Trials in EGFRm+ NSCLC
Vera Hirsh(Taipei Veterans General Hospital), J.C-H. Yang(National Taiwan University Hospital), Isaku Okamoto(Kyushu University), Carl Samuelsen(Boehringer Ingelheim (United States)), Nobuyuki Yamamoto(Wakayama Medical University), Caicun Zhou(Tongji University), Kenneth J. O’Byrne(Translational Research Institute), Martin Schüler(German Cancer Research Center), Cheng-ping Hu(Central South University), Dan Massey(Taipei Veterans General Hospital), Sarayut Lucien Geater(Prince of Songkla University), Michael Palmer(Blueprint Medicines (United States)), Tony Mok(Chinese University of Hong Kong), Yun Wu, Lecia V. Sequist(Harvard University), N. Dickgreber(Medizinische Hochschule Hannover), Riyaz Shah(Maidstone and Tunbridge Wells NHS Trust), S. Lu(Nanjing University of Chinese Medicine), Yunchao Huang(North China University of Water Resources and Electric Power), Junming Feng(Jiangsu Cancer Hospital), Angela Märten(Boehringer Ingelheim (United States)), Michael Sebastian(Mahlo (Germany)), E.H. Tan(National Cancer Centre Singapore)
Cited by 0
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k